Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb;19(2):196-203.
doi: 10.1513/AnnalsATS.202103-295OC.

Epidemiology of Idiopathic Pulmonary Fibrosis among U.S. Veterans, 2010-2019

Bhavika Kaul  1   2 , Joyce S Lee  3 , Ning Zhang  2 , Eric Vittinghoff  4 , Kathleen Sarmiento  1   2 , Harold R Collard  1 , Mary A Whooley  1   4   2
Affiliations

Epidemiology of Idiopathic Pulmonary Fibrosis among U.S. Veterans, 2010-2019

Bhavika Kaul et al. Ann Am Thorac Soc. 2022 Feb.

Abstract

Rationale: The development of novel therapies for idiopathic pulmonary fibrosis (IPF) has brought increased attention to the population burden of disease. However, little is known about the epidemiology of IPF among U.S. Veterans. Objectives: This study examines temporal trends in incidence and prevalence, patient characteristics, and risk factors associated with IPF among a national cohort of U.S. Veterans. Methods: We used data from the Veterans Health Administration (VHA) electronic health record system to describe the incidence, prevalence, and geographic distribution of IPF between January 1, 2010, and December 31, 2019. We evaluated patient characteristics associated with IPF using multivariate logistic regression. Results: Among 10.7 million Veterans who received care from the VHA between 2010 and 2019, 139,116 (1.26%) were diagnosed with IPF. Using a narrow case definition of IPF, the prevalence increased from 276 cases per 100,000 in 2010 to 725 cases per 100,000 in 2019. The annual incidence increased from 73 cases per 100,000 person-years in 2010 to 210 cases per 100,000 person-years in 2019. Higher absolute incidence and prevalence rates were noted when a broader case definition of IPF was used. Risk factors associated with IPF among Veterans included older age, White race, tobacco use, and rural residence. After accounting for interactions, the average marginal difference in IPF prevalence between males and females was small. There was significant geographic heterogeneity of disease across the United States. Conclusions: This study is the first comprehensive epidemiologic analysis of IPF among the U.S. Veteran population. The incidence and prevalence of IPF among Veterans has increased over the past decade. The effect of sex on risk of IPF was attenuated once accounting for other risk factors. The geographic distribution of disease is heterogeneous across the United States with rural residence associated with higher odds of IPF. The reasons for these trends deserve further study.

Keywords: Veterans; epidemiology; idiopathic pulmonary fibrosis; interstitial lung disease.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Veterans Health Administration idiopathic pulmonary fibrosis sample selection. VHA = Veterans Health Administration; ICD = International Classification of Disease; CT = computed tomography.
Figure 2.
Figure 2.
Annual incidence and prevalence of idiopathic pulmonary fibrosis among U.S. Veterans, 2010–2019.
Figure 3.
Figure 3.
Geographic distribution of prevalent idiopathic pulmonary fibrosis cases among U.S. Veterans (narrow case definition). State prevalence was calculated by identifying the number of unique Veterans with IPF in each state divided by total number of Veterans living in the state. IPF = idiopathic pulmonary fibrosis.
See this image and copyright information in PMC

Comment in

References

    1. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med . 2018;198:e44–e68. - PubMed
    1. Ley B, Collard HR, King TE., Jr Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med . 2011;183:431–440. - PubMed
    1. Fernández Pérez ER, Daniels CE, Schroeder DR, St. Sauver J, Hartman TE, Bartholmai BJ, et al. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest . 2010;137:129–137. - PMC - PubMed
    1. Kaunisto J, Salomaa ER, Hodgson U, Kaarteenaho R, Myllärniemi M. Idiopathic pulmonary fibrosis--a systematic review on methodology for the collection of epidemiological data. BMC Pulm Med . 2013;13:53. - PMC - PubMed
    1. Raghu G, Chen SY, Yeh WS, Maroni B, Li Q, Lee YC, et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. Lancet Respir Med . 2014;2:566–572. - PubMed

Publication types